Hematology/Oncology

Top Story

Black men at greater risk for preclinical prostate cancer, metastatic progression

April 24, 2017

An estimated 30% to 43% of black men develop asymptomatic prostate cancer by the age of 85 years, making them 28% to 56% more likely to develop preclinical prostate cancer than men of other races, according to results of a modeling study published in Cancer.

Black men also appeared more likely to experience progression to metastatic disease, results showed.

Roswell Park Cancer Institute names department chairman

April 23, 2017
John Krolewski , MD, PhD, has been named chair of the department of cancer genetics and genomics at Roswell Park Cancer Institute. Krolewski — who…

Terms of Abbott acquisition of Alere changed, lawsuits dropped

April 23, 2017
Abbott and Alere announced that the terms for Abbott’s pending acquisition of Alere have been amended and the companies have ceased litigation against each other…

Association of Community Cancer Centers names 2017-2018 president

April 22, 2017
Mark S. Soberman , MD, MBA, FACS, has been elected president of the Association of Community Cancer Centers for the 2017-2018 term. Soberman —…
Meeting News

Sorafenib, selective internal radiation yield similar survival in HCC

April 22, 2017
AMSTERDAM — Selective internal radiation therapy failed to best Nexavar in overall survival but did yield improvements in other parameters, including quality of…
More News Headlines »
CNE CME

The Identification and Management of Immune-related Adverse Events in Patients with Cancer: Practice Essentials for Emergency Medicine Providers

This activity is supported by an educational grant from Bristol-Myers Squibb.

The incorporation of immunotherapies, especially the immune checkpoint inhibitors, into treatment regimens for patients…
More »
Video
Meeting News

VIDEO: Cappelli discusses autoimmune complications from cancer therapy

April 8, 2017
More »
Featured
American Association for Cancer Research Annual Meeting

American Association for Cancer Research Annual Meeting

CME

Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement